Compare Unilever plc (UL) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Unilever plc vs Viatris Inc — how do they compare? Unilever plc trades at $62.18 (market cap $131.86B), while Viatris Inc trades at $17.54 (market cap $19.79B). The key difference: Unilever plc is far larger — about 6.7× Viatris Inc's market cap, and Unilever plc pays the higher dividend (3.68%). Which is the better fit depends on your goals.
| UL | VTRS | |
|---|---|---|
Market Cap | $131.86B | $19.79B |
Sector | Consumer Staples | Health |
52-Week High | $74.59 | $17.39 |
52-Week Low | $55.05 | $8.74 |
Enterprise Value | $157.31B | $32.00B |
Dividend Yield | 3.68% | 2.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Unilever (UL) trades at $60.79, down 2.56% today, with a mixed technical and fundamental backdrop. The stock shows a bullish technical signal from moving averages but has missed earnings expectations in recent quarters. Revenue in 2024 was $60.76B with a net income margin of 9.45%, while the company explores strategic moves like a potential bid for Thorne and a partnership with Accenture to scale AI in manufacturing.
The outlook is balanced; strong cash flow and a high ROE of 53.32% support the dividend, but recent earnings misses and a high P/B ratio of 7.55 pose risks. Analyst sentiment is neutral with a 51.36% hold rating, reflecting cautious optimism amid execution challenges and macroeconomic headwinds.
Viatris (VTRS) trades at $17.59, up 1.74% today, with a bullish technical signal and consistent earnings beats in recent quarters. The company reported revenue of $14.3B for 2025 but posted a net loss of $3.51B, reflecting margin pressures. Positive pipeline developments include FDA acceptance of a new drug application for fast-acting meloxicam, with a PDUFA date set for December 2026. Cash flow from operations remains strong at $2.32B, supporting debt reduction efforts.
The outlook is mixed: analyst consensus targets $20.00 (13.7% upside), but profitability challenges and high debt levels pose risks. Investment appeal hinges on successful pipeline execution and margin recovery, while competitive and regulatory pressures in the generics market remain key watchpoints for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Unilever plc
Unilever is a diversified personal product (42% of 2021 sales by value), home care (20%), and packaged food (38%) company. Its brands include Knorr soups and sauces, Hellmann's mayonnaise, Lipton teas, Axe and Dove skin products, and the TRESemme haircare brand. The firm has been acquisitive in recent years
Read more on UL →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
